Search Result

Results for "

lipid-lowering

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (2) Apical Sodium-Dependent Bile Acid Transporter (1) Apoptosis (2) Autophagy (2) Bacterial (2) Biochemical Assay Reagents (1) Cytochrome P450 (5) Drug Metabolite (1) Endogenous Metabolite (3) Epoxide Hydrolase (1) Farnesyl Transferase (2) Fatty Acid Synthase (FASN) (1) Ferroptosis (2) FXR (1) HCV (2) HMG-CoA Reductase (HMGCR) (5) Isotope-Labeled Compounds (1) PPAR (7) Prostaglandin Receptor (1) RAR/RXR (1) ROR (1) SARS-CoV (1) Ser/Thr Protease (2) Thyroid Hormone Receptor (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (15) Endocrinology (3) Infection (3) Inflammation/Immunology (7) Metabolic Disease (23) Neurological Disease (4)

By Targets:

Antibiotic (2)

Apical Sodium-Dependent Bile Acid Transporter (1)

Apoptosis (2)

Autophagy (2)

Bacterial (2)

Biochemical Assay Reagents (1)

Cytochrome P450 (5)

Drug Metabolite (1)

Endogenous Metabolite (3)

Epoxide Hydrolase (1)

Farnesyl Transferase (2)

Fatty Acid Synthase (FASN) (1)

Ferroptosis (2)

FXR (1)

HCV (2)

HMG-CoA Reductase (HMGCR) (5)

Isotope-Labeled Compounds (1)

PPAR (7)

Prostaglandin Receptor (1)

RAR/RXR (1)

ROR (1)

SARS-CoV (1)

Ser/Thr Protease (2)

Thyroid Hormone Receptor (1)

By Research Areas:

Cancer (10)

Cardiovascular Disease (15)

Endocrinology (3)

Infection (3)

Inflammation/Immunology (7)

Metabolic Disease (23)

Neurological Disease (4)

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0458

Pedunculoside

Fatty Acid Synthase (FASN) Metabolic Disease

Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation .

Pedunculoside	Fatty Acid Synthase (FASN)	Metabolic Disease
Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation .

HY-115914

Lipid-lowering agent-1	Others	Others
Lipid-lowering agent-1 is a potent lipid-lowering agent. Lipid-lowering agent-1 has significant pharmacological effects on the inhibition of low-density lipoprotein cholesterol (LDLC) and promotion of high-density lipoprotein cholesterol (HDLC) production. Lipid-lowering agent-1 shows potent hypolipidemic effect in high-fat diet rats .

HY-117196

GW 9578	PPAR	Metabolic Disease Inflammation/Immunology
GW9578 is a subtype-selective PPARα agonist (EC₅₀s of 5 and 50 nM for murine and human PPAR-α) with potent lipid-lowering activity .

HY-P99773

Ongericimab JS002	Ser/Thr Protease	Cardiovascular Disease Metabolic Disease
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .

HY-P99696

Lerodalcibep LIB003	Ser/Thr Protease	Cardiovascular Disease Metabolic Disease
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .

HY-117167

KB-141	Thyroid Hormone Receptor	Cancer
KB-141 is a potent and selective TRβ agonist. The IC₅₀ values are 23.9 nM and 3.3 nM for binding affinities from displacement of T3 from hTRα1 and hTRβ1, respectively. KB-141 has anti-obesity, anti-diabetic, and lipid-lowering effects?and can be used as an anti-cholesteremic agent in vivo .

HY-16643

Linerixibat Maximum Cited Publications 10 Publications Verification GSK2330672	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease Inflammation/Immunology
Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC₅₀ of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment .

HY-116175

BIBB 515	Others	Metabolic Disease
BIBB 515 is a potent, selective and orally active 2,3-oxidosqualene cyclase (OSC) inhibitor with ED₅₀ values of 0.2-0.5 mg/kg and 0.36-33.3 mg/kg in rats and mice (1-5 hours), respectively. BIBB 515 exerts lipid-lowering effect mainly by inhibiting the production of low-density lipoprotein (LDL) .

HY-B1028S

Pantethine-15N2 D-Pantethine-¹⁵N₂; LBF disulfide-¹⁵N₂	Isotope-Labeled Compounds	Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Pantethine- ¹⁵N₂ is the ¹⁵N₂ labeled Pantethine. Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .

HY-115938

BEC2

Others Metabolic Disease

BEC2 is an ester derivative of Baicalin, with good lipid-lowering activity. BEC2 can direct activate the carnitine palmitoyltransferase 1A (CPT1A) .

BEC2	Others	Metabolic Disease
BEC2 is an ester derivative of Baicalin, with good lipid-lowering activity. BEC2 can direct activate the carnitine palmitoyltransferase 1A (CPT1A) .

HY-17408

Mevastatin 5+ Cited Publications Compactin; ML236B	HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G₀/G₁ phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment .

HY-119546

Pinolenic acid PNLA	Others	Inflammation/Immunology
Pinolenic acid (PNLA) is a polyunsaturated fatty acid that can be isolated from Pinus orientalis and Pinus pinaster seed oil. Pinolenic acid has anti-inflammatory and lipid-lowering activities .

HY-14925

Lapaquistat 1 Publications Verification T-91485	Endogenous Metabolite Drug Metabolite	Metabolic Disease
Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy .

HY-16421

Ragaglitazar (-)-DRF 2725; NNC 61-0029	PPAR	Metabolic Disease
Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

HY-101692

AZ-1355	Prostaglandin Receptor	Metabolic Disease Endocrinology
AZ-1355 is an effctive lipid-lowering compound, which also inhibits platelet aggregation in vivo and elevates the prostaglandin I₂/thromboxane A₂ ratio in vitro.

HY-123632

(3S,5S)-Atorvastatin sodium salt	Cytochrome P450	Others
(3S,5S)-Atorvastatin sodium salt is a pregnane X receptor (PXR) activator and the inactive enantiomer of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor with lipid-lowering capabilities .

HY-B0258

Gemfibrozil 1 Publications Verification CI-719	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-B1028

Pantethine 1 Publications Verification D-Pantethine; LBF disulfide	Endogenous Metabolite SARS-CoV	Cardiovascular Disease Neurological Disease Inflammation/Immunology Endocrinology Cancer
Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .

HY-B0258S

Gemfibrozil-d6 CI-719-d₆	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-109567

Gemcabene PD-72953	Others	Metabolic Disease Inflammation/Immunology
Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .

HY-109523

Cerivastatin sodium	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-109567A

Gemcabene calcium PD-72953 calcium	Others	Metabolic Disease Inflammation/Immunology
Gemcabene calcium (PD-72953 calcium), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .

HY-129458

Cerivastatin	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-100313A

YM-53601 2 Publications Verification	Farnesyl Transferase HCV	Infection Metabolic Disease
YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC₅₀ of 79 nM. Lipid-lowering agent . YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .

HY-B0258R

Gemfibrozil (Standard) 1 Publications Verification CI-719 (Standard)	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil (Standard) is the analytical standard of Gemfibrozil. This product is intended for research and analytical applications. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-100313

YM-53601 free base	Farnesyl Transferase HCV	Metabolic Disease
YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC₅₀ of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .

HY-17408R

Mevastatin (Standard) Compactin(Standard); ML236B (Standard)	HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Mevastatin (Standard) is the analytical standard of Mevastatin. This product is intended for research and analytical applications. Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G₀/G₁ phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment .

HY-101701

Hepronicate

Megrin
Others Cardiovascular Disease

Hepronicate is a peripheral vasodilator with blood lipid lowering action.

Hepronicate Megrin	Others	Cardiovascular Disease
Hepronicate is a peripheral vasodilator with blood lipid lowering action.

HY-106281A

Bemfivastatin hemicalcium PPD 10558 hemicalcium	HMG-CoA Reductase (HMGCR)	Cardiovascular Disease Metabolic Disease
Bemfivastatin (PPD 10558) hemicalcium is an orally active lipid-lowering agent and HMG-CoA reductase inhibitor. Bemfivastatin hemicalcium enhances the activity of liver extracts. Bemfivastatin hemicalcium has no-observed adverse effect levels (NOAEL) with dosages of ≥320 mg/kg/d (rat developmental toxicity), ≥12.5 mg/kg/d (rabbit maternal toxicity), ≥25 mg/kg/d (rabbit developmental toxicity), respectively. Bemfivastatin hemicalcium can be used in the study of statin-related hypercholesterolemic myalgia in statin-intolerant patients.

HY-15387

Beclobrate

Sgd 24774
Others Cardiovascular Disease

Beclobrate (Sgd 24774), a Fibric acid derivative, displays remarkable lipid lowering activity in rodents .

Beclobrate Sgd 24774	Others	Cardiovascular Disease
Beclobrate (Sgd 24774), a Fibric acid derivative, displays remarkable lipid lowering activity in rodents .

HY-W144096

Methyl 2,4,6-trihydroxybenzoate	Others	Metabolic Disease Cancer
Methyl 2,4,6-trihydroxybenzoate is a metabolite of 2,4,6-trihydroxybenzoate and exhibits properties as an antioxidant, lipid lowering and anticancer activities .

HY-124187

Pinolenic acid ethyl ester Ethyl pinolenate	Biochemical Assay Reagents	Others
Pinolenic acid is a polyunsaturated fatty acid found in the seed oils of red pine (Pinus orientalis) and maritime pine (Pinus pinaster). Both oils were found to have lipid-lowering properties. A diet containing marine pine nut oil (MPSO) reduces HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to reduce cholesterol efflux in vitro. Korean pine nut oil supplements may help obesity by reducing appetite. People who take this oil experience an increase in the satiety hormones CCK and GLP-1 and a decrease in appetite. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not metabolized to arachidonic acid and can reduce the level of arachidonic acid in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.

HY-100976

LUF6283
LUF6283 is a potent and orally active HCA(2) partial agonist, with a K_i of 0.55 µM. LUF6283 can achieve the beneficial lipid lowering effect of niacin without producing the unwanted cutaneous flushing side effect .

HY-N7971

2-Hydroxy-1-Methoxyaporphine	Endogenous Metabolite	Cardiovascular Disease
2-Hydroxy-1-Methoxyaporphine is an alkaloid that can be isolated from Nelumbo nucifera. 2-Hydroxy-1-Methoxyaporphine is the major active ingredient of the Chinese traditional medicine Jiang-Zhi-Ning .

HY-163436

F44-A13	FXR Cytochrome P450 RAR/RXR PPAR ROR	Metabolic Disease
F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC₅₀ value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders .

HY-121538

CUDA	Epoxide Hydrolase PPAR	Cardiovascular Disease
CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC₅₀s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .

Pinolenic acid ethyl ester Ethyl pinolenate	Biochemical Assay Reagents
Pinolenic acid is a polyunsaturated fatty acid found in the seed oils of red pine (Pinus orientalis) and maritime pine (Pinus pinaster). Both oils were found to have lipid-lowering properties. A diet containing marine pine nut oil (MPSO) reduces HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to reduce cholesterol efflux in vitro. Korean pine nut oil supplements may help obesity by reducing appetite. People who take this oil experience an increase in the satiety hormones CCK and GLP-1 and a decrease in appetite. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not metabolized to arachidonic acid and can reduce the level of arachidonic acid in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.

Ongericimab JS002	Ser/Thr Protease	Cardiovascular Disease Metabolic Disease
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .

Lerodalcibep LIB003	Ser/Thr Protease	Cardiovascular Disease Metabolic Disease
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0458

Pedunculoside	Aquifoliaceae Triterpenes Classification of Application Fields Terpenoids Ilex rotunda Thunb. Source classification Metabolic Disease Plants Disease Research Fields	Fatty Acid Synthase (FASN)
Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation .